In ovarian cancer cells, thioridazine inhibits VEGF-induced angiogenesis by inhibiting FAK and Src phosphorylation.18 However, identification of the anticancer molecular mechanism of thioridazine requires further study. The gene discussed is PTK2; the disease is ovarian carcinoma.